Cat. No.: HY-10892

Copy Link Print Information

HEPT

HEPT is a potent and selective anti-HIV-1 agent.

For research use only. We do not sell to patients.

CAS No.: 123027-56-5
Formula: C₁₄H₁₆N₂O₄S
Molecular Weight:308.35

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (268 KB)

HEPT Chemical Structure

CAS No.: 123027-56-5

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

HEPT is a potent and selective anti-HIV-1 agent^[1].

All HIV Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
CCRF-CEM	EC₅₀	>100 μM Compound: 5 (HEPT)	Inhibitory effect against HIV-2 replication in CEM /TK-(thymidine kinase deficient) cells. Inhibitory effect against HIV-2 replication in CEM /TK-(thymidine kinase deficient) cells.	[PMID: 7538589]
CCRF-CEM	EC₅₀	>100 μM Compound: 5 (HEPT)	Inhibitory effect against HIV-2 replication in CEM cells. Inhibitory effect against HIV-2 replication in CEM cells.	[PMID: 7538589]
CCRF-CEM	CC₅₀	>1 μM Compound: HEPT	Concentration which reduces the cell viability by 50% (CEM-SS / MT-4) Concentration which reduces the cell viability by 50% (CEM-SS / MT-4)	[PMID: 9191961]
CCRF-CEM	CC₅₀	400 μM Compound: HEPT	Cytotoxic concentration for inhibition of HTLB-IIIB replication in CEM cells. Cytotoxic concentration for inhibition of HTLB-IIIB replication in CEM cells.	[PMID: 9240351]
CCRF-CEM	EC₅₀	8.3 μM Compound: HEPT	Effective concentration for inhibition of HTLB-IIIB replication in CEM cells. Effective concentration for inhibition of HTLB-IIIB replication in CEM cells.	[PMID: 9240351]
CEM-SS	IC₅₀	2 μM Compound: HEPT	Effective concentration required to achieve 50% inhibition of HIV-1 multiplication in human T-4 lymphoblastoid cell line CEM-SS/LAI Effective concentration required to achieve 50% inhibition of HIV-1 multiplication in human T-4 lymphoblastoid cell line CEM-SS/LAI	[PMID: 9191961]
Lymphocyte	EC₅₀	5.5 μg/mL Compound: HEPT	Concentration required to inhibit HIV-1 induced cytopathicity in human MT-4 lymphocyte cells. Concentration required to inhibit HIV-1 induced cytopathicity in human MT-4 lymphocyte cells.	[PMID: 1495006]
MT4	CC₅₀	740 μM Compound: 1	Concentration required to reduce viability of mock-infected MT-4 cells Concentration required to reduce viability of mock-infected MT-4 cells	[PMID: 1469700]
MT4	EC₅₀	7 μM Compound: 1	Effective concentration required for 50% protection of MT-4 cells against the cytopathic effect of HIV-1 Effective concentration required for 50% protection of MT-4 cells against the cytopathic effect of HIV-1	[PMID: 1469700]
MT4	CC₅₀	>200 μg/mL Compound: HEPT	Concentration required to reduce human MT-4 cell viability by 50%. Concentration required to reduce human MT-4 cell viability by 50%.	[PMID: 1495006]
MT4	CC₅₀	405 μM Compound: HEPT	Cytotoxic concentration that reduces the MT-4 cell viability by 50% Cytotoxic concentration that reduces the MT-4 cell viability by 50%	[PMID: 15149669]
MT4	IC₅₀	>405 μM Compound: HEPT	Inhibitory concentration against SO561945 (HIV 1 mutant RT) viral infection of MT-4 cells Inhibitory concentration against SO561945 (HIV 1 mutant RT) viral infection of MT-4 cells	[PMID: 15149669]
MT4	IC₅₀	5.06 μM Compound: HEPT	Concentration required to protect the cell against HIV-1 strain IIIB viral cytopathogenicity by 50% in MT-4 cells Concentration required to protect the cell against HIV-1 strain IIIB viral cytopathogenicity by 50% in MT-4 cells	[PMID: 15149669]
MT4	CC₅₀	405 μM Compound: 1, HEPT	Cytotoxicity against MT4 cells after 4 days by MTT method Cytotoxicity against MT4 cells after 4 days by MTT method	[PMID: 17095124]
MT4	IC₅₀	>405.8 μM Compound: 1, HEPT	Antiviral activity against HIV2 ROD in MT4 cells after 4 days by MTT method Antiviral activity against HIV2 ROD in MT4 cells after 4 days by MTT method	[PMID: 17095124]
MT4	IC₅₀	5.06 μM Compound: 1, HEPT	Antiviral activity against HIV1 3B in MT4 cells after 4 days by MTT method Antiviral activity against HIV1 3B in MT4 cells after 4 days by MTT method	[PMID: 17095124]
MT4	CC₅₀	740 μM Compound: HEPT	Concentration of compound required to reduce the viability of mock-infected HIV-2 (LAV-2ROD)/MT-4 cells by 50% Concentration of compound required to reduce the viability of mock-infected HIV-2 (LAV-2ROD)/MT-4 cells by 50%	[PMID: 1732552]
MT4	CC₅₀	743 μM Compound: HEPT	Concentration required to reduce the viability of mock-infected MT-4 cells by 50%. Concentration required to reduce the viability of mock-infected MT-4 cells by 50%.	[PMID: 1732552]
MT4	EC₅₀	>250 μM Compound: HEPT	Concentration required inhibit HIV-2 (LAV-2ROD)replication in MT-4 cells. Concentration required inhibit HIV-2 (LAV-2ROD)replication in MT-4 cells.	[PMID: 1732552]
MT4	EC₅₀	7 μM Compound: HEPT	Concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1. Concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1.	[PMID: 1732552]
MT4	CC₅₀	405 μM Compound: HEPT	Cytotoxicity against MT4 cells after 4 days by MTT method Cytotoxicity against MT4 cells after 4 days by MTT method	[PMID: 17381078]
MT4	IC₅₀	5.06 μM Compound: HEPT	Antiviral activity against wild type HIV1 3B in MT4 cells after 4 days by MTT method Antiviral activity against wild type HIV1 3B in MT4 cells after 4 days by MTT method	[PMID: 17381078]
MT4	IC₅₀	>405.38 μM Compound: HEPT	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	[PMID: 18692274]
MT4	IC₅₀	5.06 μM Compound: HEPT	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	[PMID: 18692274]
MT4	CC₅₀	≤399 μM Compound: HEPT	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	[PMID: 18692274]
MT4	CC₅₀	>500 μM Compound: HEPT	Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells (HIV-1 HTLV-IIIB strain) by 50% was determined on 4th day after virus infection. Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells (HIV-1 HTLV-IIIB strain) by 50% was determined on 4th day after virus infection.	[PMID: 1992136]
MT4	CC₅₀	740 μM Compound: HEPT	Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50% Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50%	[PMID: 1992136]
MT4	EC₅₀	>250 μM Compound: HEPT	Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-2 ((LAV-2EHO strain) and determined on 4th day after virus infection. Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-2 ((LAV-2EHO strain) and determined on 4th day after virus infection.	[PMID: 1992136]
MT4	EC₅₀	>250 μM Compound: HEPT	Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-2 (LAV-2ROD strain) and determined on 4th day after virus infection. Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-2 (LAV-2ROD strain) and determined on 4th day after virus infection.	[PMID: 1992136]
MT4	EC₅₀	6.5 μM Compound: HEPT	Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 (HTLV-IIIB strain) and determined on 4th day after virus infection. Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 (HTLV-IIIB strain) and determined on 4th day after virus infection.	[PMID: 1992136]
MT4	EC₅₀	7 μM Compound: HEPT	Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 (HTLV-IIIB). Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 (HTLV-IIIB).	[PMID: 1992136]
MT4	EC₅₀	8.1 μM Compound: HEPT	Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 (HTLV-IIIRF strain) and determined on 4th day after virus infection. Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 (HTLV-IIIRF strain) and determined on 4th day after virus infection.	[PMID: 1992136]
MT4	CC₅₀	740 μM Compound: HEPT	Cytotoxic concentration of compound required to reduce the viability of mock infected MT-4 cells against the HIV-1 (HTLV-IIIB)induced cytopathic effect Cytotoxic concentration of compound required to reduce the viability of mock infected MT-4 cells against the HIV-1 (HTLV-IIIB)induced cytopathic effect	[PMID: 2016715]
MT4	EC₅₀	>250 μM Compound: HEPT	Inhibitory activity against HIV-2(LAV-2EHO strain) replication in MT-4 cells Inhibitory activity against HIV-2(LAV-2EHO strain) replication in MT-4 cells	[PMID: 2016715]
MT4	EC₅₀	>250 μM Compound: HEPT	Inhibitory activity against HIV-2(LAV-2ROD strain) replication in MT-4 cells Inhibitory activity against HIV-2(LAV-2ROD strain) replication in MT-4 cells	[PMID: 2016715]
MT4	EC₅₀	7 μM Compound: HEPT	Inhibitory activity against HIV-1 (HTLV-IIIB strain) replication in MT-4 cells Inhibitory activity against HIV-1 (HTLV-IIIB strain) replication in MT-4 cells	[PMID: 2016715]
MT4	EC₅₀	8.1 μM Compound: HEPT	Inhibitory activity against HIV-1 (HTLV-IIIRF strain) replication in MT-4 cells Inhibitory activity against HIV-1 (HTLV-IIIRF strain) replication in MT-4 cells	[PMID: 2016715]
MT4	CC₅₀	>500 μM Compound: 1	Concentration of compound required to reduce the viability of mock infected MT-4 cells against HIV-1 by 50% Concentration of compound required to reduce the viability of mock infected MT-4 cells against HIV-1 by 50%	[PMID: 2016729]
MT4	EC₅₀	6.5 μM Compound: 1	Concentration of compound required to achieve 50% protection of MT-4 cells against HIV-1 virus induced cytopathic effect Concentration of compound required to achieve 50% protection of MT-4 cells against HIV-1 virus induced cytopathic effect	[PMID: 2016729]
MT4	CC₅₀	>25 μg/mL Compound: HEPT	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 22652226]
MT4	EC₅₀	3.28 μM Compound: HEPT	Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days	[PMID: 22652226]
MT4	IC₅₀	5.15 μM Compound: 35	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection from cytopathic effect Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection from cytopathic effect	[PMID: 24657566]
MT4	CC₅₀	740 μM Compound: 5e	Cytotoxic concentration of compound required to reduce the viability of mock-infected MT-4 cells by 50% Cytotoxic concentration of compound required to reduce the viability of mock-infected MT-4 cells by 50%	[PMID: 2479745]
MT4	EC₅₀	7 μM Compound: 5e	Concentration required to achieve 50% protection of MT-4 cells against cytopathic effect of HIV-1 Concentration required to achieve 50% protection of MT-4 cells against cytopathic effect of HIV-1	[PMID: 2479745]
MT4	CC₅₀	740 μM Compound: 1; HEPT	Cytotoxicity against human MT4 cells assessed as reduction in cell viability Cytotoxicity against human MT4 cells assessed as reduction in cell viability	[PMID: 36442370]
MT4	EC₅₀	6.5 μM Compound: HEPT	Compound was evaluated for effective concentration required to achieve 50% protection of MT-4 cells against cytopathic effect of HIV-1 Compound was evaluated for effective concentration required to achieve 50% protection of MT-4 cells against cytopathic effect of HIV-1	[PMID: 7540209]
MT4	CC₅₀	740 μM Compound: HEPT	Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50% Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50%	[PMID: 7636846]
MT4	EC₅₀	7 μM Compound: HEPT	Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 virus. Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 virus.	[PMID: 7636846]
MT4	IC₅₀	11 μM Compound: HEPT	Effective concentration required to achieve 50% inhibition of HIV-1 multiplication in human T-4 lymphoblastoid cell line MT-4 IIIB Effective concentration required to achieve 50% inhibition of HIV-1 multiplication in human T-4 lymphoblastoid cell line MT-4 IIIB	[PMID: 9191961]
MT4	CC₅₀	740 μM Compound: 1	Cytotoxic concentration required to reduce viability of mock-infected MT-4 cells by 50% Cytotoxic concentration required to reduce viability of mock-infected MT-4 cells by 50%	10.1016/S0960-894X(00)80042-6
MT4	EC₅₀	7 μM Compound: 1	Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1	10.1016/S0960-894X(00)80042-6
Vero	EC₅₀	>100 μM Compound: 1	Antiviral activity against Vero cells, infected with HSV-1. Antiviral activity against Vero cells, infected with HSV-1.	[PMID: 1720175]
Vero	IC₅₀	>100 μM Compound: 1	The compound was tested for toxicity in Vero cells. The compound was tested for toxicity in Vero cells.	[PMID: 1720175]

Chemical Information

CAS No. 123027-56-5
Molecular Weight 308.35
Formula C₁₄H₁₆N₂O₄S
SMILES

O=C1NC(C(C)=C(SC2=CC=CC=C2)N1COCCO)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (268 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Tanaka H, et al. A new class of HIV-1-specific 6-substituted acyclouridine derivatives: synthesis and anti-HIV-1 activity of 5- or 6-substituted analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT). J Med Chem. 1991 Jan;34(1):349-57. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

HEPT

All HIV Isoforms

Biological Activity

Chemical Information

Purity & Documentation

References

Calculators

Help & FAQs

HEPT Related Classifications

HY-10892 Related Classifications